Head-to-head evidence
Olanzapine (Zyprexa) vs Risperidone (Risperdal Consta)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00712686 · Phase 3 · completed
The study was a large randomized, double-blind, active-controlled comparison of aripiprazole and olanzapine, with clinical outcomes including PANSS symptom scores. Because the registry does not report whether either primary endpoint was met, the treatment comparison cannot be judged as positive, negative, or mixed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Risperidone (Risperdal Consta)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa)'s landscape · Risperidone (Risperdal Consta)'s landscape